Casper Marc N, Chairman & CEO, has demonstrated a clear selling bias in recent transactions, particularly involving Thermo Fisher Scientific (TMO). Over 225 reported trades across two companies, his total sell transactions amount to $127.1 million, significantly outweighing his $43.8 million in buys. The recent activity shows an accelerated divestment pattern, with 23 sales in March 2026 alone—all concentrated in TMO shares. On March 5, 2026, he executed 13 separate sales ranging from $10,073 to $582,033, alongside a $1.24 million market purchase. The prior day saw similarly structured transactions, including seven sales between $60,976 and $701,166, plus a $1.55 million buy.
The transactions reveal a methodical unwinding of positions, with March 3-5 sales totaling approximately $5.8 million against $2.8 million in purchases during the same period. While the market purchases suggest ongoing position management, the scale and frequency of sales—particularly the clustering of mid-six-figure disposals—indicate a sustained reduction in exposure. The absence of recent buys in the filing history further reinforces this directional trend. Notably, all activity centers on TMO, with no trades disclosed for other holdings during this period, pointing to a focused adjustment in this single security. The mixed transaction codes (both open market and derivative dispositions) suggest a structured approach to liquidity events rather than discretionary trading.
AI-assisted summary